Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9vHPV Vaccine to Prevent Oral HPV in Men Living With HIV
NCT04255849Phase 3Active, not recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Feb 2021
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Weill Cornell Medicine. Started Feb 2021; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT04255849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04255849.